Attention!

What is the drug LANGOTER®

LANGOTER® is an anti-tumor agent. As a selective tyrosine kinase inhibitor, LANGOTER® inhibits tumor growth, metastasis and angiogenesis, and accelerates apoptosis of tumor cells.

It inhibits the growth of various human tumor cell lines and increases the antitumor activity of chemotherapeutic drugs, radiation and hormone therapy.

Clinical data suggest that gefitinib significantly increases the time to disease progression in patients with locally advanced or metastatic non-small cell lung cancer.

Dosage form

Round biconvex tablets, covered with a film-coated brown color. On a cross-section, the tablet core is white or almost white in color.

Indications for use

Locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.